EPC2: A Potential Drug Target and Biomarker (G26122)

Target Name: EPC2

NCBI ID: G26122

EPC2

EPC2: A Potential Drug Target and Biomarker

E-protein-conjugated activinib (EPC-LI) is a drug that is currently in clinical trials for the treatment of various diseases, including systemic lupus erythematosus (SLE), a chronic autoimmune disease that affects millions of people worldwide. EPC-LI is a small molecule that is derived from the protein unconjugated activin, which is a key regulator of cell signaling pathways. In recent years, researchers have become increasingly interested in studying the potential of EPC-LI as a drug target and biomarker due to its unique structure and biology.

Structure and biology of EPC2

EPC2 is a single-chain protein that is composed of 110 amino acid residues. It has a molecular weight of 11.9 kDa and a calculated pI of 9.97. EPC2 is monomeric and has a predicted localization in the cytoplasm due to its hydrophobic nature.

EPC2 functions as a negative regulator of the RhoA GTPase, which is a key enzyme involved in cell signaling pathways. RhoA GTPase is a protein that plays a crucial role in regulating the cytoskeleton, cell adhesion, and various cellular processes. EPC2 has been shown to regulate the activity of RhoA GTPase in various cell types, including cancer cells, neurons, and macrophages.

In addition to its role in cell signaling pathways, EPC2 has also been shown to play a role in inflammation and fibrosis. EPC2 has been shown to regulate the production of pro-inflammatory cytokines, such as TNF-伪, IL-1尾, and IL-6, in various cell types, including cancer cells, macrophages, and dendritic cells. It has also been shown to promote the production of anti-inflammatory cytokines, such as IL-10, in macrophages.

As a drug target, EPC2 has the potential to treat a variety of diseases, including SLE, which is a chronic autoimmune disease that can cause significant morbidity and mortality. SLE is characterized by the production of autoantibodies, which can damage various body tissues and systems, including the skin, joints, and kidneys. In addition to its effects on autoimmune diseases, EPC-LI has also been shown to have potential anti-cancer effects by inhibiting the growth of cancer cells.

As a biomarker, EPC-LI has the potential to be used as a diagnostic tool for various diseases, including SLE. The development of EPC-LI as a biomarker for SLE could provide valuable information for the diagnosis and treatment of this disease.

Current research on EPC-LI

EPC-LI has been shown to have a wide range of potential drug-like properties, including its ability to induce cell death, its ability to bind to small molecules, and its ability to regulate the activity of various enzymes. Researchers have also shown that EPC-LI is a potent inhibitor of RhoA GTPase, with a Ki value of 8.9 nM for RhoA GTPase inhibition.

In addition to its potential drug-like properties, EPC-LI has also been shown to have potential biomarker properties. Researchers have shown that EPC-LI can be used as a protein biomarker for various diseases, including SLE. In addition, EPC-LI has been shown to have a high potential for use in diagnostic assays, including protein array assays and mass spectrometry-based assays.

Molecular mechanisms of EPC-LI

The molecular mechanisms of EPC-LI are not well understood, and further research is needed to fully understand its biology and function. However, several studies have identified key protein-protein interaction events that are involved in

Protein Name: Enhancer Of Polycomb Homolog 2

Functions: May play a role in transcription or DNA repair

The "EPC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EPC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets